Efficacy of garenoxacin in patients with macrolide-resistant Mycoplasma pneumoniae pneumonia.

The prevalence of macrolide-resistant Mycoplasma pneumoniae in Japan is increasing once again. The therapeutic efficacy of quinolone garenoxacin was compared with minocycline, which is recommended as the first-choice drug in patients with macrolide-resistant M. pneumoniae pneumonia. Defervescence within 48 h after initiation of antibiotics was observed in 90.6% of garenoxacin and 90% of minocycline recipients. Our results indicated that garenoxacin can be considered as the first-choice drug for the treatment of macrolide-resistant M. pneumoniae pneumonia.